Targeted Oncologics ISO Companion Diagnostics To Find Attractive Patients
Executive Summary
The molecularly targeted oncologics that have energized oncology drug development and treatment over the last decade have sparked a secondary boom in companion diagnostics. After all, a drug for a tumor expressing a particular receptor profile is not particularly useful unless physicians can identify patients with that profile.
You may also be interested in...
FDA Reestablishes Imaging Drugs Committee, Citing Application Surge
The increasing number of new medical imaging drugs FDA is asked to review has led the agency to reestablish an advisory committee devoted exclusively to them.
FDA Reestablishes Imaging Drugs Committee, Citing Application Surge
The increasing number of new medical imaging drugs FDA is asked to review has led the agency to reestablish an advisory committee devoted exclusively to them.
On The Horizon: Planned Filings For Novel Drugs In 2011
On top of the full slate of pending applications, the pool of potential novel product approvals in 2011 continues to grow as more submissions come in.